- Home
- FIVE vs RVMD Comparison
FIVE vs RVMD Comparison
Compare FIVE & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIVE
- RVMD
- Stock Information
- Founded
- FIVE 2002
- RVMD 2014
- Country
- FIVE United States
- RVMD United States
- Employees
- FIVE N/A
- RVMD N/A
- Industry
- FIVE Department/Specialty Retail Stores
- RVMD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FIVE Consumer Discretionary
- RVMD Health Care
- Exchange
- FIVE Nasdaq
- RVMD Nasdaq
- Market Cap
- FIVE 6.7B
- RVMD 7.5B
- IPO Year
- FIVE 2012
- RVMD 2020
- Fundamental
- Price
- FIVE $134.05
- RVMD $37.48
- Analyst Decision
- FIVE Buy
- RVMD Strong Buy
- Analyst Count
- FIVE 19
- RVMD 12
- Target Price
- FIVE $115.94
- RVMD $68.67
- AVG Volume (30 Days)
- FIVE 1.7M
- RVMD 3.0M
- Earning Date
- FIVE 06-04-2025
- RVMD 08-06-2025
- Dividend Yield
- FIVE N/A
- RVMD N/A
- EPS Growth
- FIVE N/A
- RVMD N/A
- EPS
- FIVE 4.78
- RVMD N/A
- Revenue
- FIVE $4,035,191,000.00
- RVMD N/A
- Revenue This Year
- FIVE $16.13
- RVMD N/A
- Revenue Next Year
- FIVE $9.97
- RVMD $241.39
- P/E Ratio
- FIVE $27.32
- RVMD N/A
- Revenue Growth
- FIVE 10.71
- RVMD N/A
- 52 Week Low
- FIVE $52.38
- RVMD $29.17
- 52 Week High
- FIVE $137.30
- RVMD $62.40
- Technical
- Relative Strength Index (RSI)
- FIVE 72.73
- RVMD 38.51
- Support Level
- FIVE $121.11
- RVMD $36.61
- Resistance Level
- FIVE $133.33
- RVMD $40.70
- Average True Range (ATR)
- FIVE 3.68
- RVMD 1.54
- MACD
- FIVE -0.49
- RVMD -0.44
- Stochastic Oscillator
- FIVE 93.13
- RVMD 7.43
About FIVE Five Below Inc.
Five Below Inc is a specialty value retailer offering merchandise targeted at the tween and teen demographic. The Company's edited assortment of products includes select brands and licensed merchandise. It derives revenue from sales of the Company's merchandise to customers.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.